Dr. Lal Path Labs Ltd. has informed the Exchange about Senior Management Personnel
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal Path Labs reported FY2026 revenue of Rs 27,629 million, up 12.2% from Rs 24,614 million in FY2025. Net profit grew to Rs 5,098 million from Rs 4,922 million, a 3.6% increase. The Board recommended a final dividend of Rs 4 per share (total annual dividend Rs 20.5 per share including Rs 16.5 interim dividends). Key expansions include acquisition of 100% stake in Shahbazkers Diagnostic Centre and incorporation of a new wholly-owned subsidiary in Dubai. Two senior management personnel (Dr. Reena Nakra and Dr. Saloni Khera) were designated as SMPs. Auditors gave clean (unmodified) opinions on both standalone and consolidated results. The 32nd AGM is scheduled for July 25, 2026.
Strong financial performance with consistent revenue growth and shareholder-friendly dividend policy. The Dubai subsidiary and acquisition of SDCPL signal continued geographic and operational expansion, which could support long-term growth prospects for investors.